Ontology highlight
ABSTRACT:
SUBMITTER: Anderson SL
PROVIDER: S-EPMC5813471 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
European endocrinology 20170822 2
Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that new drugs developed and studied for the treatment of T2D must undergo CV safety testing. Since the advent of this new policy, canagliflozin, empagliflozin, liraglutide and semaglutide have demonstrat ...[more]